For Research Use OnlyNot for Human Consumption

Research Hubs

Grouped entry points for the three topic families that already carry the clearest intent across the library: core retatrutide research, approval-status tracking, and UAE/GCC market guides.

Start Here

Six routes that answer the most common research questions. Use these before drilling into the compound library.

Compound Library

Structured profiles for the active obesity-pipeline molecules. Each card lists receptor profile and development stage; open the profile for clinical data and protocol context.

Protocol & Tools

Practical references for handling, dosing, and reconstituting investigational pens.

UAE, GCC & Lebanon Guides

Country and emirate pages covering availability, regulation, and verification context.

Comparisons

Head-to-head pages for the compounds people compare most. Trial results, receptor activity, and approval stage in one view.

Approval & Regulation

Freshness-sensitive pages. Updated as readouts and filings publish.

Research Standards

Trust and due-diligence depth: COA documentation, legality, sourcing, and beginner reference.

All Research Library

Every EN research page on Remy Peptides — 77 articles grouped into 6 categories for full discoverability. Cards list alphabetically within each group.

Retatrutide (8)

Deep-dive coverage of retatrutide — profile, dosing, pen hardware, side effects, half-life, and supplier checklists.

Supplier Checklist

Buy Retatrutide in Dubai: Supplier Checklist 2026

Guide to evaluating retatrutide suppliers in Dubai: COA verification, pricing red flags, pen vs vial selection, and UAE research-use compliance.

Open
Dosage FAQ

Retatrutide Dosage FAQ (2026)

Retatrutide dosage FAQ covering titration, pen clicks, missed doses, storage, and semaglutide switching. Updated for 2026 research data.

Open
Dosage

Retatrutide Dosage Guide: Phase 3 Titration Protocol

Retatrutide dosage calculator plus titration schedule: 2mg start, 4mg/9mg/12mg maintenance, pen click conversion, and dose-hold rules from the TRIUMPH trials.

Open
Pharmacokinetics

Retatrutide Half-Life: Why Once-Weekly Dosing Works

Retatrutide half-life is about 6 days in published Lilly research. See the PK data, why once-weekly dosing works, and how long washout may take.

Open
Clicks Reference

How Many Clicks Is 1mg of Retatrutide? 30mg Pen Clicks Guide

Exact retatrutide 30mg pen click lookup: 1mg = 10 clicks, 2mg = 20, 2.5mg = 25, 4mg = 40, 6mg = 60, with split-dose rules above 6mg.

Open
Pen Hardware

Retatrutide 30mg Pen Guide: Specs, Storage & Priming

Device guide for the retatrutide 30mg pen: 300 clicks total, 0.1mg per click, storage rules, priming steps, 60-click max dial, and needle compatibility.

Open
Profile

Retatrutide — Triple Agonist GLP-1/GIP/Glucagon Profile

Eli Lilly's triple agonist for GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH data, mechanism, and positioning vs tirzepatide and CagriSema.

Open
Safety

Retatrutide Side Effects: GI Rates, Safety Signals & Clinical Comparison

Dose-by-dose nausea, diarrhea, and vomiting rates from retatrutide Phase 2 (NEJM 2023) and TRIUMPH Phase 3 trials. Discontinuation data and GLP-1 comparisons.

Open

Compound Profiles & Research (14)

Mechanism profiles and research data for individual compounds across the peptide and GLP-1 landscape.

AMPK Activator

AICAR (Acadesine): AMPK Activator Research

AICAR acadesine research data: AMPK activation mechanism, exercise mimetic findings, fat oxidation, glucose uptake, and metformin comparison.

Open
hGH Fragment

AOD-9604 Research: hGH Fragment Data and Evidence Limits

hGH fragment biology, preclinical lipolysis data, failed obesity-development history, and why the human evidence base stays weak.

Open
Compound Profile

CagriSema — GLP-1 + Amylin Combination Profile

CagriSema: GLP-1 + amylin combination from Novo Nordisk in Phase 3 REDEFINE programme. Mechanism, trial data, and positioning vs retatrutide.

Open
Neuroprotective

Cerebrolysin: Neuroprotective Peptide Research

Cerebrolysin neuroprotective peptide research: BDNF and NGF neurotrophic factors, blood-brain barrier penetration, stroke recovery, and Semax comparison.

Open
Senolytic

FOXO4-DRI Research: Senolytic Peptide Data & Mechanism

FOXO4-DRI senolytic peptide research: FOXO4-p53 disruption, D-retro-inverso stability, senescent cell clearance, and dasatinib+quercetin comparison.

Open
Aesthetic

Looksmaxxing Peptides — Science Behind the Trend

Looksmaxxing peptides reviewed: GHK-Cu, BPC-157, MK-677, GLP-1 body composition & collagen synthesis. Evidence-based breakdown of each compound.

Open
Injection Guide

Mounjaro (Tirzepatide) Injection Guide

Mounjaro (tirzepatide) injection guide: mechanism, clinical weight loss data, dosing schedule, side effects, UAE cost & Ozempic comparison.

Open
Compound Profile

Orforglipron — Oral Non-Peptide GLP-1 Profile

Eli Lilly's oral non-peptide GLP-1 agonist, FDA-approved as Foundayo. Mechanism, ACHIEVE and ATTAIN trial data, and positioning vs injectable GLP-1s.

Open
Melanocortin

PT-141 (Bremelanotide) Research: Melanocortin Peptide Data

Melanocortin receptor pharmacology, human trial observations, blood-pressure signal, pigmentation findings, and conservative research-only framing.

Open
Oral GLP-1

Rybelsus — Oral Semaglutide Tablets

Rybelsus dosing starts at 3mg, titrates to 14mg. Weight loss data, GI side effects, UAE pricing in AED, and how the oral GLP-1 compares to Ozempic.

Open
Compound Profile

Semaglutide — GLP-1 Receptor Agonist Profile

Novo Nordisk's GLP-1 receptor agonist. Mechanism, STEP and SUSTAIN Phase 3 data, Ozempic/Wegovy/Rybelsus differences, and next-gen positioning.

Open
Mitochondrial

SS-31 (Elamipretide) Research: Mitochondrial Peptide Data

SS-31 elamipretide research data: cardiolipin binding, ATP production, mitochondrial membrane stabilization, Barth syndrome trials, and aging findings.

Open
GHRH Analog

Tesamorelin Research: GHRH Analog Data and Clinical Limits

GHRH analog biology, HIV lipodystrophy trial data, liver-fat findings in HIV-associated NAFLD, and the label limits researchers need to keep in view.

Open
Compound Profile

Survodutide — Dual GLP-1/Glucagon Agonist Profile

Survodutide: dual GLP-1/glucagon agonist in Phase 3 SYNCHRONIZE programme. Mechanism, trial IDs, efficacy data, and positioning vs retatrutide.

Open

Comparisons (11)

Head-to-head data tables and format guides comparing molecules, vial workflows, dosing schedules, and tolerability profiles.

Ranking

Best Obesity Drug in 2026: 8-Drug Decision Guide

Decision guide comparing 8 obesity drugs by efficacy, route, tolerability, and approval stage, with verdicts for approved, pipeline, and oral options.

Open
Head-to-Head

CagriSema vs Tirzepatide — REDEFINE 4 Results

REDEFINE 4 head-to-head: CagriSema 20.2% vs tirzepatide 23.6% weight loss at 84 weeks. Full data breakdown and mechanism comparison.

Open
Oral Options

Oral Obesity Drugs in 2026: Wegovy Pill vs Orforglipron vs VK2735

Review oral obesity drug candidates in 2026, including orforglipron, VK2735, and related approval-status and comparison pages.

Open
Safety

Ozempic vs Mounjaro vs Wegovy: Side Effects Compared (2026 Data)

Ozempic, Mounjaro & Wegovy side effects compared from trial data. Nausea, GI effects, injection-site reactions & adverse event frequencies.

Open
Dosage

Retatrutide vs Semaglutide vs Tirzepatide: Dosage Comparison

Side-by-side dosage comparison of retatrutide, semaglutide, and tirzepatide — titration schedules, dose ranges, and Phase 3 clinical outcomes.

Open
Head-to-Head

Retatrutide vs Orforglipron: Injectable vs Oral GLP-1

Retatrutide wins on efficacy (28.7% vs 12.4%), orforglipron wins on convenience (pill vs injection). Full data table, mechanisms & 2026 approval…

Open
3-Way

Retatrutide vs Tirzepatide vs CagriSema

Three-way 2026 comparison of retatrutide, tirzepatide, and CagriSema across weight-loss data, blood-sugar effects, safety, and market stage.

Open
Head-to-Head

Saxenda vs Ozempic

Ozempic delivers 2.4x more weight loss than Saxenda (STEP 8 trial). Side-by-side dosing, cost, side effects & which one researchers recommend.

Open
Head-to-Head

Survodutide vs Retatrutide — Dual Agonist vs Triple Agonist

Survodutide hits ~19% weight loss (Phase 2), retatrutide hits 28.7% (Phase 3). Both use glucagon — but the triple agonist pulls ahead. Full comparison.

Open
Price & Data

Weight Loss Injections Dubai Price Guide

Weight loss injections Dubai price guide for 2026: compare Mounjaro, Wegovy, Ozempic, Saxenda, and research-use retatrutide by monthly cost, access, and data.

Open
Head-to-Head

Zenagamtide vs CagriSema: Single Molecule vs Fixed-Dose Combination

Zenagamtide (single molecule) vs CagriSema (fixed-dose combo): both target GLP-1/amylin but differ structurally. Mechanism, data & pipeline.

Open

Approval Trackers & Pipeline (12)

Freshness pages on FDA, EMA, and NDA status — plus pipeline timelines and Phase 3 trial readouts.

Approval Deep Dive

Foundayo (Orforglipron) Deep Dive 2026 | Pricing & Impact

Secondary Foundayo deep dive covering pricing, label context, oral GLP-1 positioning, and market impact after approval. Use the status page for approval.

Open
Status Page

Is CagriSema FDA Approved? No — Status April 2026

CagriSema FDA approval tracker: Novo Nordisk NDA, REDEFINE Phase 3 (22.7% weight loss), expected decision window. Updated April 2026.

Open
Status Page

Is Oral VK2735 Approved in 2026?

Viking's oral VK2735 hit 12.2% weight loss in just 13 weeks — and Phase 3 is coming. Could it beat orforglipron to market? Full trial data and timeline.

Open
Status Page

Is Orforglipron Approved? Yes, Approved as Foundayo

Yes. Orforglipron was FDA approved on April 1, 2026 as Foundayo. Start here for the direct status answer, then open the deeper market-impact page.

Open
Status Page

Is Retatrutide FDA Approved in 2026?

Track retatrutide's current FDA status as of April 2026: Phase 3 TRIUMPH readouts, Lilly's NDA watch, and the remaining 2026 regulatory milestones ahead.

Open
Status Page

Survodutide FDA Approval Status 2026: Phase 3, MASH and Timeline

Survodutide is not FDA approved as of April 2, 2026. Track SYNCHRONIZE, SYMPHONY, Phase 2 results, and the earliest NDA timeline.

Open
Master Tracker

Obesity Drug Approval Tracker 2026: Status Hub, NDAs & Pipeline

Live 2026 tracker of every obesity drug: FDA approvals, NDA filings, Phase 3 readouts. Retatrutide, CagriSema, orforglipron, survodutide — status at a glance.

Open
Pipeline

Obesity Drug Pipeline Timeline 2026

2026 obesity-drug pipeline calendar with filing dates, Phase 3 readouts, FDA decision windows, launch timing, and major catalysts across key programs.

Open
Pipeline

Petrelintide: Roche & Zealand’s Amylin Analog for Obesity

Petrelintide: once-weekly amylin analog by Roche & Zealand. ZUPREME-1 Phase 2: 10.7% weight loss, zero vomiting. Phase 3 timeline included.

Open
Master Tracker

Retatrutide TRIUMPH Trial Tracker

Track retatrutide TRIUMPH milestones, readout timing, safety signals, and how the data feeds Lilly's approval timeline. Use the status page for approval.

Open
Pipeline

Survodutide: Dual GLP-1/Glucagon Agonist for Obesity & MASH

Survodutide: dual GLP-1/glucagon agonist, 18.7% weight loss in Phase 2. FDA Breakthrough Therapy for MASH. Mechanism & retatrutide comparison.

Open
Pipeline

Zenagamtide (Amycretin): Phase 3 Status & FDA Approval Tracker — April 2026

Zenagamtide (amycretin) April 2026 research update: observed 14.5% weight change at 36 weeks, GLP-1/amylin mechanism, and Phase 3 status.

Open

UAE, GCC & Lebanon Market (18)

Country and emirate-level research coverage — Dubai, Abu Dhabi, KSA, Qatar, Lebanon, and UAE-wide market context.

Dubai

Are Peptides Legal in Dubai?

See what UAE medicine and customs rules cover, where research-use peptide listings fit, and how to verify a supplier in Dubai.

Open
Dubai

Biohacking with Research Peptides in Dubai 2026

Biohacking peptide research in Dubai: compounds, verification standards, and how triple-pathway research fits current 2026 protocols.

Open
Dubai

GHK-Cu Dubai | Copper Peptide Skin Data

GHK-Cu research data on collagen, fibroblasts, skin density, and the GHK-Cu + BPC-157 + TB-500 protocol. UAE availability with PubMed citations.

Open
Dubai

GLOW 50/10/10 Dubai

Three-compound blend guide covering GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, reference pricing, and current restock status.

Open
UAE

GLP-1 Medications in the UAE

Compare UAE GLP-1 medication prices, access rules, prescription context, insurance notes, and research-use retatrutide context for 2026.

Open
Dubai

Mounjaro Dubai: Price, Prescription & Pharmacy Access

Live April 2026 Dubai price signals for Mounjaro, including UAE pharmacy listings, clinic-package ranges, prescription requirements, and coverage context.

Open
Lebanon

Mounjaro in Lebanon

Mounjaro in Lebanon: MOPH visibility, tirzepatide verification, counterfeit-risk signals, and how it differs from investigational retatrutide.

Open
Qatar

Mounjaro in Qatar

Mounjaro and tirzepatide in Qatar: pharmacy/clinic signals, prescription checks, and how it differs from investigational retatrutide.

Open
UAE

Obesity in the UAE: 2026 Statistics & The GLP-1 Research Landscape

UAE obesity statistics 2026: prevalence by emirate, demographics, diabetes rates & the growing GLP-1 market. Data from 440,000+ adult study.

Open
Dubai

Ozempic in Dubai

Ozempic in Dubai is prescription-only semaglutide, usually AED 744 to AED 1,800 per month, with broader UAE pharmacy availability than Mounjaro or Wegovy.

Open
UAE

Peptide Trends in UAE and Worldwide 2026

2026 peptide trends in UAE and globally — GLP-1 agonists, BPC-157, oral peptides and the $49.68B market. Top types and research insights.

Open
UAE

Research Peptides in the UAE

Research peptides in the UAE with supplier verification steps, COA proof, delivery context, and current public product availability for Dubai researchers.

Open
UAE

Retatrutide Clinical Trials UAE

No UAE-listed sites appeared in the registrational retatrutide study records reviewed for this page. See trial status, data, and site verification.

Open
Dubai

Retatrutide Dubai | UAE Availability, COA & Verification

Retatrutide in Dubai: UAE research-use availability, Janoshik COA proof, pen-format details, and supplier-verification steps for laboratory buyers.

Open
Dubai

Retatrutide 20mg Pen Dubai

20mg pen guide with 200-click math, Janoshik pen batch RET-20-C-2604-001, 99.841% HPLC purity, and tiered AED pricing.

Open
Dubai

Retatrutide 40mg Vial Dubai

40mg lyophilised vial guide covering reconstitution workflow, cost per mg, cold-chain dispatch, and when labs choose vial over pen.

Open
KSA

Retatrutide in Saudi Arabia

Retatrutide in Saudi Arabia: investigational status, enforcement signals, tirzepatide comparison, and how to verify research-only claims.

Open
UAE

Wegovy Price & Dosing Guide UAE

Wegovy (semaglutide 2.4 mg) UAE: AED 1,200-1,500/month, 5-step titration, STEP 1 data (14.9% loss) & pharmacy availability. Research context.

Open

Protocols, Safety & Tools (13)

Reconstitution, storage, mixing, sourcing, legality, blend rationale, body-composition impact, and adverse-event references.

Reconstitution

How to Reconstitute Peptides with Bacteriostatic Water

How to reconstitute peptides with bacteriostatic water: step-by-step mixing, concentration math, sterile handling, storage rules, and research-use guidance.

Open
Blend Guide

CJC-1295 + Ipamorelin Guide: What Is Studied and What Is Not

Component evidence for CJC-1295 and ipamorelin, ghrelin-plus-GHRH synergy logic, blend rationale, and where the direct evidence still stops short.

Open
Discontinuation

What Happens When You Stop GLP-1 Medications?

Weight regain data after stopping GLP-1s. Semaglutide, tirzepatide & liraglutide discontinuation studies with timelines and trial results.

Open
Body Composition

GLP-1 & Muscle Loss — Composition Data (2026)

Does GLP-1 cause muscle loss? Lean mass data from semaglutide, tirzepatide & retatrutide trials. Body composition research & protein strategies.

Open
Signal Detection

GLP-1 Side Effects in Online Communities — 410,198 Reddit Posts

NLP analysis of 410,198 Reddit posts identified 67,008 self-reported semaglutide & tirzepatide users. What the signals add — and don’t add — to trial data.

Open
Comorbidity

Which Obesity Drugs Actually Matter for Sleep Apnea?

Zepbound is the only obesity drug FDA-approved for sleep apnea. Retatrutide studying OSA in TRIUMPH-3. Trial data, AHI reduction & pipeline.

Open
Side Effect

Ozempic Face

Ozempic face: why GLP-1 drugs cause facial fat loss, which drugs carry higher risk, clinical prevalence data & how retatrutide compares.

Open
Outcome Data

Ozempic & Mounjaro Before and After

Ozempic averages 15% and Mounjaro 22.5% weight loss at 72 weeks. See clinical before-and-after data at 3, 6, and 12 months with body composition breakdown.

Open
Mixing

What Not to Mix with Peptides

What not to mix with peptides: reconstitution compatibility, peptide-peptide mixing rules, supplement interactions, medication overlap, and storage conflicts.

Open
Sourcing

Peptide Raw Powder Sourcing: 2026 Supplier Guide

How to vet peptide powder suppliers in 2026: HPLC CoA red flags, third-party testing standards, cold-chain logistics & B2B pricing benchmarks.

Open
COA Guide

Peptide COA Guide: HPLC & Safety Tests

How to read HPLC purity, assay, LC-MS identity, endotoxin, TFA, heavy metals, and Janoshik batch checks without getting lost in lab jargon.

Open
Storage

Peptide Stability & Storage

Peptide stability & storage guide: lyophilized shelf life, reconstituted stability, solvents & storage temps for retatrutide, BPC-157 & more.

Open
Primer

What Are Peptides? A Beginner’s Research Guide

Beginner's guide to peptide types, mechanisms, reconstitution, storage, legality, and quality verification for research use in 2026.

Open